St. Jude Medical Announces Leading Sponsorship Of Landmark Clinical Trial To Study Atrial Fibrillation

St. Jude Medical, Inc. (NYSE:STJ) today announced that it is the leading sponsor of the Catheter Ablation Versus Anti-arrhythmic Drug Therapy for Atrial Fibrillation (CABANA) Trial.

This entry was posted on Monday, June 15th, 2009 at 3:00 pm and is filed under Heart, Heart Disease. You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.

Leave a Reply

You must be logged in to post a comment.